NCCN Collaborates with AVEO and Astellas on Innovative Cancer Research

NCCN recently received a research grant from AVEO Pharmaceuticals and Astellas Pharma, Inc. to evaluate the role of tivozanib in the treatment of solid tumors. Tivozanib is a potent, selective, long half-life inhibitor of all three VEGF receptors that is designed to optimize VEGF blockade while minimizing off-target toxicities. FORT WASHINGTON, PA – The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) today announced that it has e...
Source: National Comprehensive Cancer Network Oncology Research Program - Category: Cancer & Oncology Source Type: news